AGLE logo

Aeglea BioTherapeutics (AGLE) Cash From Operations

Annual CFO

-$80.14 M
-$26.43 M-49.20%

December 31, 2022

Summary

Performance

1-Year Change

-49.2%

3-Year Change

-22%

5-Year Change

-225.59%

15-Year Change

-225.59%

AGLE Cash From Operations Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

High & Low

All-time High

-$7.33 M

3-Year Low

-$80.14 M
AGLE annual cash flow from operations is currently at its 3-year low

Earnings dates

Last Annual Earnings Report Date

Dec 31, 2022
AGLE previous annual earnings announcement was published on Dec 31, 2022

Next Annual Earnings Report Date

N/A
AGLE next annual earnings announcement has not yet been scheduled

OtherAGLEcash flowmetrics:

Annual CFI

$57.01 M
AGLE annual cash flow from investing activities is $57.01 million

Annual CFF

$42.68 M
AGLE annual cash flow from financing activities is $42.68 million

Annual FCF

-$80.18 M
AGLE annual free cash flow is -$80.18 million

Annual CAPEX

$38.00 K
AGLE annual capital expenditures is $38.00 thousand

Quarterly CFO

-$34.60 M
-$17.95 M-107.88%

September 30, 2023

Summary

Performance

3-Month Change

-107.88%

1-Year Change

-129.61%

3-Year Change

-97.29%

5-Year Change

-306.93%

AGLE Quarterly CFO Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

High & Low

All-time High

$2.08 M
AGLE quarterly cash flow from operations is currently -1761.72% below its historical high of $2.08 million

3-Year Low

-$34.60 M
AGLE quarterly cash flow from operations is currently at its 3-year low

Earnings dates

Last Quarterly Earnings Report Date

Sep 30, 2023
AGLE previous earnings announcement was published on Sep 30, 2023

Next Quarterly Earnings Report Date

N/A
AGLE next earnings announcement has not yet been scheduled

OtherAGLEcash flowmetrics:

Quarterly CFI

-$97.63 M
AGLE quarterly cash flow from investing activities is -$97.63 million

Quarterly CFF

-$12.53 M
AGLE quarterly cash flow from financing activities is -$12.53 million

Quarterly FCF

-$34.60 M
AGLE quarterly free cash flow is -$34.60 million

Quarterly CAPEX

-
AGLE quarterly capital expenditures value is unknown

TTM CFO

-$87.01 M
-$19.53 M-28.94%

September 30, 2023

Summary

Performance

3-Month Change

-28.94%

1-Year Change

-7.07%

3-Year Change

-16.12%

5-Year Change

-32.46%

AGLE TTM CFO Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

High & Low

All-time High

-$1.34 M

3-Year Low

-$87.01 M
AGLE TTM cash flow from operations is currently at its 3-year low

Earnings dates

Last Quarterly Earnings Report Date

Sep 30, 2023
AGLE previous earnings announcement was published on Sep 30, 2023

Next Quarterly Earnings Report Date

N/A
AGLE next earnings announcement has not yet been scheduled

OtherAGLEcash flowmetrics:

TTM CFI

-$59.12 M
AGLE TTM cash flow from investing activities is -$59.12 million

TTM CFF

$197.46 M
AGLE TTM cash flow from financing activities is $197.46 million

TTM FCF

-$87.01 M
AGLE TTM free cash flow is -$87.01 million

TTM CAPEX

-
AGLE TTM capital expenditures value is unknown

Cash From Operations Formula

CFO = Net Income + Non Cash Expenses + Changes In Working Capital

AGLE Cash From Operations Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1 y1 year-49.2%-129.6%-7.1%
3 y3 years-22.0%-97.3%-16.1%
5 y5 years-225.6%-306.9%-32.5%

AGLE Cash From Operations Highs & Lows

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs lowTTM vs highTTM vs highTTM vs lowTTM vs low
3 y3-year+49.2%at low+129.6%at low+62.0%at low
5 y5-year+49.2%at low-1761.7%at low+68.7%at low
alltimeall time+992.6%at low-1761.7%at low+6388.7%at low

Aeglea BioTherapeutics Cash From Operations History

DateAnnualQuarterlyTTM
Sep 2023
-
-$34.60 M(+107.9%)
-$87.01 M(+28.9%)
Jun 2023
-
-$16.64 M(-5.6%)
-$67.48 M(-5.6%)
Mar 2023
-
-$17.63 M(-2.8%)
-$71.52 M(-10.8%)
Dec 2022
-$80.14 M(+49.2%)
-$18.14 M(+20.4%)
-$80.14 M(-1.4%)
Sep 2022
-
-$15.07 M(-27.1%)
-$81.27 M(-2.3%)
Jun 2022
-
-$20.67 M(-21.3%)
-$83.20 M(+37.6%)
Mar 2022
-
-$26.26 M(+36.3%)
-$60.45 M(+12.5%)
Dec 2021
-$53.72 M(-29.1%)
-$19.27 M(+13.3%)
-$53.72 M(+4.1%)
Sep 2021
-
-$17.00 M(-916.5%)
-$51.58 M(-1.0%)
Jun 2021
-
$2.08 M(-110.7%)
-$52.12 M(-29.2%)
Mar 2021
-
-$19.53 M(+14.0%)
-$73.61 M(-2.9%)
Dec 2020
-$75.78 M(+15.3%)
-$17.13 M(-2.3%)
-$75.78 M(+1.1%)
Sep 2020
-
-$17.54 M(-9.7%)
-$74.94 M(+0.4%)
Jun 2020
-
-$19.41 M(-10.5%)
-$74.61 M(+4.2%)
Mar 2020
-
-$21.69 M(+33.1%)
-$71.58 M(+9.0%)
Dec 2019
-$65.69 M(+104.1%)
-$16.29 M(-5.3%)
-$65.69 M(+16.1%)
Sep 2019
-
-$17.21 M(+5.0%)
-$56.60 M(+18.2%)
Jun 2019
-
-$16.38 M(+3.6%)
-$47.89 M(+18.1%)
Mar 2019
-
-$15.81 M(+119.5%)
-$40.55 M(+26.0%)
DateAnnualQuarterlyTTM
Dec 2018
-$32.19 M(+30.8%)
-$7.20 M(-15.3%)
-$32.19 M(+4.3%)
Sep 2018
-
-$8.50 M(-6.0%)
-$30.87 M(+3.8%)
Jun 2018
-
-$9.04 M(+21.4%)
-$29.73 M(+11.6%)
Mar 2018
-
-$7.45 M(+26.8%)
-$26.63 M(+8.2%)
Dec 2017
-$24.61 M(+30.7%)
-$5.87 M(-20.3%)
-$24.61 M(+6.6%)
Sep 2017
-
-$7.37 M(+24.0%)
-$23.10 M(+7.0%)
Jun 2017
-
-$5.94 M(+9.4%)
-$21.59 M(+6.5%)
Mar 2017
-
-$5.43 M(+24.7%)
-$20.28 M(+7.7%)
Dec 2016
-$18.84 M(+71.6%)
-$4.36 M(-25.7%)
-$18.84 M(+23.0%)
Sep 2016
-
-$5.87 M(+26.6%)
-$15.32 M(+15.5%)
Jun 2016
-
-$4.63 M(+16.1%)
-$13.26 M(+6.2%)
Mar 2016
-
-$3.99 M(+378.8%)
-$12.49 M(+13.7%)
Dec 2015
-$10.98 M(+49.7%)
-$833.00 K(-78.1%)
-$10.98 M(-16.3%)
Sep 2015
-
-$3.81 M(-1.1%)
-$13.12 M(+18.1%)
Jun 2015
-
-$3.85 M(+55.3%)
-$11.12 M(+31.1%)
Mar 2015
-
-$2.48 M(-16.5%)
-$8.48 M(+15.6%)
Dec 2014
-$7.33 M
-$2.98 M(+65.1%)
-$7.33 M(+68.2%)
Sep 2014
-
-$1.80 M(+48.1%)
-$4.36 M(+70.4%)
Jun 2014
-
-$1.22 M(-9.2%)
-$2.56 M(+90.8%)
Mar 2014
-
-$1.34 M
-$1.34 M

FAQ

  • What is Aeglea BioTherapeutics annual cash flow from operations?
  • What is the all time high annual CFO for Aeglea BioTherapeutics?
  • What is Aeglea BioTherapeutics annual CFO year-on-year change?
  • What is Aeglea BioTherapeutics quarterly cash flow from operations?
  • What is the all time high quarterly CFO for Aeglea BioTherapeutics?
  • What is Aeglea BioTherapeutics quarterly CFO year-on-year change?
  • What is Aeglea BioTherapeutics TTM cash flow from operations?
  • What is the all time high TTM CFO for Aeglea BioTherapeutics?
  • What is Aeglea BioTherapeutics TTM CFO year-on-year change?

What is Aeglea BioTherapeutics annual cash flow from operations?

The current annual CFO of AGLE is -$80.14 M

What is the all time high annual CFO for Aeglea BioTherapeutics?

Aeglea BioTherapeutics all-time high annual cash flow from operations is -$7.33 M

What is Aeglea BioTherapeutics annual CFO year-on-year change?

Over the past year, AGLE annual cash flow from operations has changed by -$26.43 M (-49.20%)

What is Aeglea BioTherapeutics quarterly cash flow from operations?

The current quarterly CFO of AGLE is -$34.60 M

What is the all time high quarterly CFO for Aeglea BioTherapeutics?

Aeglea BioTherapeutics all-time high quarterly cash flow from operations is $2.08 M

What is Aeglea BioTherapeutics quarterly CFO year-on-year change?

Over the past year, AGLE quarterly cash flow from operations has changed by -$19.53 M (-129.61%)

What is Aeglea BioTherapeutics TTM cash flow from operations?

The current TTM CFO of AGLE is -$87.01 M

What is the all time high TTM CFO for Aeglea BioTherapeutics?

Aeglea BioTherapeutics all-time high TTM cash flow from operations is -$1.34 M

What is Aeglea BioTherapeutics TTM CFO year-on-year change?

Over the past year, AGLE TTM cash flow from operations has changed by -$5.74 M (-7.07%)